What the FDA labels say about taking them together
Primaquine and rivaroxaban
Primaquine's FDA label of February 11, 2026 names rivaroxaban in its drug interactions section; the rivaroxaban labels PlainMeds reads (2) do not name primaquine. The primaquine label: “CYP3A4 Substrates Refer to the Prescribing Information for a CYP3A substrate where minimal concentration changes may lead to serious adverse reactions for the recommended dosage modification and/or monitoring.”
Check it at the source: the primaquine FDA label on DailyMed (effective February 11, 2026, Sanofi-Aventis U.S. LLC); the rivaroxaban FDA label on DailyMed (effective September 10, 2026, Janssen Pharmaceuticals, Inc.).
What does the primaquine label say about rivaroxaban?
Primaquine label, drug interactionsCYP3A4 Substrates Refer to the Prescribing Information for a CYP3A substrate where minimal concentration changes may lead to serious adverse reactions (e.g. rivaroxaban, calcineurin inhibitors, ergot derivatives, tyrosine kinase inhibitors) for the recommended dosage modification and/or monitoring.
Source: FDA drug label (Primaquine Phosphate), Sanofi-Aventis U.S. LLC, effective February 11, 2026 (SPL set 1bfbf4ae-81b8-4160-a00d-6322aadd4b59), via openFDA; the full label on DailyMed
What does the rivaroxaban label say about primaquine?
Rivaroxaban's label (effective September 10, 2026) and its 1 other brand-application label do not name primaquine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Xarelto), Janssen Pharmaceuticals, Inc., effective September 10, 2026 (SPL set 10db92f9-2300-4a80-836b-673e1ae91610), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Primaquine | Rivaroxaban | |
|---|---|---|
| Labeled for | n/a | Atrial fibrillation, Heart attack and coronary artery disease, Blood clots (DVT and PE), Stroke prevention |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.650 per tablet 2.5 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once